ArticleHealth science reports2026
Efficacy of Dextromethorphan Augmentation in SSRI-Resistant Obsessive-Compulsive Disorder: A Randomized Controlled Trial.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Obsessive-compulsive disorder (OCD) is a chronic condition associated with marked functional impairment and high rates of treatment resistance. Converging evidence implicates glutamatergic dysregulation in OCD pathophysiology. Dextromethorphan (DXM), an N-methyl-d-aspartate (NMDA) receptor antagonist with additional monoaminergic and sigma-1 receptor activity, may modulate this system. This study evaluated the safety and efficacy of DXM augmentation in adults with moderate to severe OCD receiving stable SSRI treatment. Methods: In this randomized, double-blind, placebo-controlled pilot trial 40 adults with moderate to severe OCD (Y-BOCS > 16) and inadequate response to at least 12 weeks of adequate-dose SSRI monotherapy were assigned to DXM (15 mg twice daily) or matched placebo, in addition to their ongoing SSRI, for 12 weeks. OCD symptom severity was assessed using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) at baseline, week 4, and week 12. Repeated-measures analysis of variance (ANOVA) was used to examine changes over time. The primary outcome was the time × group interaction in Y-BOCS. Secondary outcomes were not assessed. Trial registration: IRCT20221227056943N1; Ethics approval: IR.ZUMS.REC.1401.236. Results: Baseline demographic and clinical characteristics were similar between groups. The DXM group showed a significant reduction in Y-BOCS scores from 26.55 ± 6.19 at baseline to 16.30 ± 6.94 at week 12, whereas the placebo group remained relatively unchanged. Repeated-measures ANOVA revealed a significant group × time interaction ( Conclusion: Dextromethorphan augmentation significantly reduced OCD symptom severity in patients with partial response to SSRIs, supporting its potential role as an adjunctive treatment. These findings warrant larger, longer-term trials to confirm efficacy, determine optimal dosing, and clarify neurobiological mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.